Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Using Daily Self-administered Indirect Moxibustion to Zusanli St-36 to Reduce Chemotherapy Induced Pancytopenia: a Feasibility Study

NCT02781155 is registered in ClinicalTrials.gov with East and North Hertfordshire NHS Trust as lead sponsor.

NCT NCT02781155
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02781155 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Using Daily Self-administered Indirect Moxibustion to Zusanli St-36 to Reduce Chemotherapy Induced Pancytopenia: a Feasibility Study
Lead sponsor
East and North Hertfordshire NHS Trust
Phase
Phase 1/2
Overall status
Unknown status
Start date
February 29, 2016
Completion date
September 30, 2017
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, colorectal neoplasms, genital neoplasms, female, toxicity due to chemotherapy